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Abstract
Background:  Gemcitabine, a deoxycytidine nucleoside analog, is the current standard
chemotherapy used as first-line treatment for patients with locally advanced or metastatic cancer
of the pancreas, and extends life survival by 5.7 months. Advanced pancreatic cancer thus remains
a highly unmet medical need and new therapeutic agents are required for this patient population.
Troxacitabine (Troxatyl™) is the first unnatural L-nucleoside analog to show potent preclinical
antitumor activity and is currently under clinical investigation. Troxacitabine was recently evaluated
as a first-line therapy in 54 patients with advanced adenocarcinoma of the pancreas and gave
comparable overall results to those reported with gemcitabine in recently published randomized
trials.
Methods: The human pancreatic adenocarcinoma cell lines, AsPC-1, Capan-2, MIA PaCa-2 and
Panc-1, were exposed to troxacitabine or gemcitabine alone or in combination, for 72 h, and the
effects on cell growth were determined by electronic particle counting. Synergistic efficacy was
determined by the isobologram and combination-index methods of Chou and Talalay. Mechanistic
studies addressed incorporation of troxacitabine into DNA and intracellular levels of troxacitabine
and gemcitabine metabolites. For in vivo studies, we evaluated the effect of both drugs, alone and in
combination, on the growth of established human pancreatic (AsPC-1) tumors implanted
subcutaneously in nude mice. Statistical analysis was calculated by a one-way ANOVA with Dunnett
as a post-test and the two-tailed unpaired t test using GraphPad prism software.
Results: Synergy, evaluated using the CalcuSyn Software, was observed in all four cell-lines at
multiple drug concentrations resulting in combination indices under 0.7 at Fa of 0.5 (50% reduction
of cell growth). The effects of drug exposures on troxacitabine and gemcitabine nucleotide pools
were analyzed, and although gemcitabine reduced phosphorylation of troxacitabine when cells
were exposed at equal drug concentrations, there was no effect on phosphorylated pools at drug
combinations that were synergistic. The amount of troxacitabine incorporated into DNA was also
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not affected by the presence of gemcitabine. In vivo testing against a human pancreatic (AsPC-1)
xenograft mouse tumor model indicated that both drugs were more than additive at well-tolerated
doses and schedule. The biological basis for this synergy is unclear as we did not observe changes
in apoptosis, DNA repair, troxacitabine incorporation into DNA or troxacitabine metabolism in
the presence of gemcitabine.
Conclusion: These data, together with phase I clinical data showing tolerability of both agents
when combined, suggest combination therapy with troxacitabine and gemcitabine warrants further
evaluation in advanced pancreatic cancer patients.
Background
Pancreatic adenocarcinoma is one of the leading causes of
cancer death with mortality rates almost identical to inci-
dence rates [1]. Diagnosis usually occurs at late stages,
making surgical intervention almost unfeasible due to low
survival rates [2]. 5-Fluorouracil (5-FU), a previous stand-
ard treatment for advanced pancreatic adenocarcinoma,
had a modest response rate of 20% and achieved median
survivals of only 2–6 months [3]. Gemcitabine (GEMZAR;
Eli Lilly), a cell-cycle specific inhibitor of DNA synthesis
and ribonucleotide reductase, has been directly compared
to 5-FU in a randomized phase III study in advanced ade-
nocarcinoma of the pancreas, in which gemcitabine
improved quality of life and extended survival by two
months [4]. This study led to the approval by the U.S.
Food and Drug Administration for gemcitabine as first-
line treatment for patients with locally advanced or meta-
static cancer of the pancreas. It is clear that novel thera-
peutic agents and/or combinations are needed for the
treatment of pancreatic cancer.
Troxacitabine (Troxatyl™; Shire Biochem, Inc., exclusively
licensed to SGX Pharmaceuticals, Inc.), like gemcitabine,
is a deoxycytidine nucleoside analog. Preclinical studies
demonstrated that it has broad and potent antitumor effi-
cacy against both solid and haematological human tumor
xenografts [5-9]. Moreover, troxacitabine was shown to be
active against two human pancreatic cancer cell lines,
Panc-1 and MIA PaCa-2, grown as xenografts in nude mice
[10]. In these studies, troxacitabine exhibited greater
reduction in tumor size compared to gemcitabine in Panc-
1 xenografts and equivalent activity in MIA PaCa-2
xenografts.
Troxacitabine, which has an unnatural β-L-configuration,
has different mechanistic properties compared to cytarab-
ine and gemcitabine. Troxacitabine is not a permeant for
nucleoside transporters [11], is resistant to deamination
[5,7], does not inhibit ribonucleotide reductase and is
phosphorylated to its triphosphate by 3-phosphoglycer-
ate kinase instead of nucleoside diphosphate kinase [12-
14]. In contrast to most other nucleoside analogs, intrac-
ellular accumulation of phosphorylated metabolites of
troxacitabine is proportional to its extracellular concentra-
tions [15]. In addition, inefficient removal of troxacitab-
ine within DNA by 3'→5' exonucleases may result in
prolonged retention of troxacitabine, leading to its cyto-
toxicity [16,17].
Combination therapy is a major strategy for overcoming
drug resistance and improving responses and cure rates. In
general, agents that have distinct and complementary bio-
chemical mechanisms of action are exploited for possible
biochemical synergy. The rationale for studying troxacit-
abine and gemcitabine, although structurally closely
related and both targeting DNA, in combination regimens
is provided by differences in their activation and elimina-
tion pathways. Combining two nucleoside analogs,
although a new paradigm in oncology, is a standard strat-
egy in virology. Complementary antineoplastic activity
has been documented for troxacitabine and cytarabine
[18] as well as for gemcitabine and cytarabine [19].
Because troxacitabine has potent antitumor activity in
human pancreatic xenografts [10] and gemcitabine is cur-
rently used as first-line treatment for patients with locally
advanced or metastatic cancer of the pancreas, the current
work was undertaken to determine if they can be used
concomitantly, thereby providing additive or synergistic
benefits against pancreatic cancer. We thus evaluated the
growth inhibitory potential of troxacitabine, gemcitabine,
and their combination in a panel of human pancreatic
cancer cell lines and on their in vivo antitumor efficacy
against a human pancreatic cancer (AsPC-1) xenograft.
Methods
Materials
Troxacitabine (Troxatyl™, (-)-2'-deoxy-3'-oxacytidine; Mr
= 213) was synthesized at Shire Biochem [20] and
[3H]troxacitabine (3.9 Ci/mmol) was prepared by
Moravek Biochemicals (Brea, CA). Gemcitabine hydro-
chloride for injection (GEMZAR, Eli Lilly Canada Inc.; 1 g
per vial) was purchased from the Montreal General Hos-
pital (Montreal, Canada). [5,6 3H]Uridine (specific activ-
ity of 41.2 Ci/mmol) was obtained from Moravek
Biochemicals (Brea, CA) with a purity of >97% as con-
firmed by high performance liquid chromatography
(HPLC). All other reagents used were of analytical grade
and were obtained from commercial sources. Tissue cul-BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
Page 3 of 11
(page number not for citation purposes)
ture (12-well) plates, tissue culture medium Roswell Park
Memorial Institute (RPMI) 1640 medium, Dulbecco's
Minimal Eagle's Medium (DMEM), McCoy's 5A Medium,
and fetal bovine serum were purchased from Gibco BRL
(Burlington, ON, Canada).
Growth and maintenance of cell lines
Human pancreatic adenocarcinoma cell lines, Panc-1,
Capan-2, MIA PaCa-2, and AsPC-1 were purchased from
the American Type Culture Collection (Manassas, VA.).
Stock cell lines, which were demonstrated to be free of
Mycoplasma  by PCR analysis (Stratagene, LaJolla, CA),
were routinely cultured in DMEM (Panc-1 and MIA PaCa-
2), RPMI (AsPC-1) or McCoy's 5A (Capan-2) with 10%
fetal bovine serum and maintained as adherent cultures at
37°C in a humidified atmosphere containing 5% CO2.
Glutamine, HEPES or sodium pyruvate supplements were
added to maintain proper cell growth according to the
instructions from the American Type Culture Collection.
Growth inhibition studies
Exponentially growing cells were seeded in 12-well plates
at densities of 4 × 104 (MIA PaCa-2), 3 × 104 (Panc-1), and
8 × 104 (Capan-2 and AsPc-1) cells/well and allowed to
attach for 24 h. Cells were exposed to graded concentra-
tions (three replicates) of troxacitabine or gemcitabine
either alone or in combination for 72 h. A total of eight
drug concentrations (10-3 to 10-10 M for troxacitabine and
10-5 to 10-12 M for gemcitabine) (T) plus a drug-free con-
trol (C) and a time zero (T0, time at which test compound
was added) were evaluated. At time zero and at the end of
the 72 h treatment, cells were harvested by trypsinization
and counted using electronic particle counting (Coulter
Electronics Inc., Luton, UK). Chemosensitivity values
were expressed as the drug concentration that inhibited
cell growth by 50% (GI50) [calculated from [(T-T0)/(C-
T0)] × 100 = 50, which is the drug concentration resulting
in a 50% reduction in the net cell number of drug-treated
cultures relative to the increase in control cultures during
the drug incubation period] determined from concentra-
tion-effect relationships using GraphPad prism 2.01
(GraphPad Software, San Diego, CA).
Analysis of combined drug effects
Drug synergy was determined by the isobologram and
combination-index methods, derived from the median-
effect principle of Chou and Talalay [21] using the Cal-
cuSyn software (Biosoft, Ferguson, MO). Data obtained
from the growth inhibitory experiments were used to per-
form these analyses. The isobologram method is a graph-
ical representation of the pharmacologic interaction and
is formed by selecting a desired fractional cell kill (Fa) and
plotting the individual drug doses required to generate
that Fa on their respective x- and y-axes. A straight line is
then drawn to connect the points. The observed dose
combination of the two agents that achieved that particu-
lar Fa is then plotted on the isobologram. Combination
data points that fall on the line represent an additive drug-
drug interaction, whereas data points that fall below or
above the line represent synergism or antagonism, respec-
tively. The combination-index (CI) method is a mathe-
matical and quantitative representation of a two-drug
pharmacologic interaction. Using data from the growth
inhibitory experiments and computerized software, CI
values are generated over a range of Fa levels from 0.05 –
0.90 (5% – 90% growth inhibition). A CI of 1 indicates an
additive effect between two agents, whereas a CI < 1 or CI
> 1 indicates synergism or antagonism, respectively.
Cellular uptake assays
Cellular uptake of 10 μM [3H]troxacitabine and [3H]urid-
ine by Capan-2, AsPC-1, MIA PaCa-2 and Panc-1 cells was
measured for four hours in the absence or presence of
excess unlabeled nucleoside. At the end of incubation
periods, cells were washed free of [3H] permeant and sol-
ubilised to measure cell-associated radioactivity as
described previously [11]. The uptake of uridine, a known
high-activity permeant for both equilibrative and concen-
trative nucleoside transporters [22], was examined and
compared to that of troxacitabine, which has previously
been shown to be a non-permeant of the nucleoside trans-
porters, entering cells primarily by passive diffusion [11].
Excess unlabeled troxacitabine or uridine was included
since their presence blocks mediated uptake of radiola-
beled nucleoside via nucleoside transporters. Uptake
assays were conducted in 20 mM Tris-HCl buffer contain-
ing 3 mM K2HPO4, 1 mM MgCl2.6H2O, 2 mM CaCl2, 5
mM glucose, and 130 mM NaCl (pH 7.4); 300 ± 15
mOsm and at room temperature.
Intracellular phosphorylated metabolites
Formation of tritiated metabolites of troxacitabine was
determined in AsPC-1 cells. Logarithmically growing
AsPC-1 cells (2 × 106 cells/flask) were incubated in the
presence of [3H]troxacitabine alone or in combination
with gemcitabine using equimolar drug concentrations
(10 μM [3H]troxacitabine in the presence or absence of 10
μM non-radioactive gemcitabine) or 100:1 troxacitab-
ine:gemcitabine drug concentrations (10 μM [3H]troxaci-
tabine in the presence or absence of 0.1 μM gemcitabine)
for 4 h. Formation of intracellular phosphorylated metab-
olites was also evaluated after 24-h exposures using lower
drug concentrations (300 nM [3H]troxacitabine and 0.5
nM gemcitabine). At the end of incubation periods (all at
37°C), the medium was removed and the cells were
trypsinized and washed by centrifugation with cold phos-
phate buffered saline. The cell pellets were snap frozen
and stored at -80°C until analysis by HPLC.BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
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Nucleotides were extracted from cell pellets with 10%
trichloroacetic acid (TCA), and the extracts were neutral-
ized with 1 N tri-n-octylamine in Freon as described pre-
viously [23]. The TCA insoluble pellet, representing the
nucleotides incorporated into DNA, was re-solubilized in
0.5 N NaOH and radioactivity was measured with a Beck-
man LS5000TD scintillation counter and protein levels
were determined with the Bradford protein assay (Bio-Rad
Laboratories, Mississauga, Canada). For determination of
mono-, di-, and triphosphates of troxacitabine and gem-
citabine, HPLC with online radiodetection (Canberra
Packard Canada Ltd., Montreal, Canada) and UV detec-
tion was used as described earlier [11]. Samples were ana-
lyzed with a Whatman 10 SAX (4.6 × 250 mm) column
with a linear gradient of 10 mM ammonium phosphate
(pH 2.9) to 750 mM ammonium phosphate (pH 4.1) at
flow rates of 1.5 mL/min. HPLC analysis of 15 nmol each
of troxacitabine, troxacitabine mono-, di- and triphos-
phates standards yielded retention times of 6.1, 10.4, 21.1
and 39.9 min, respectively. ATP, ADP, and AMP levels
were also determined to monitor the quality of the extrac-
tion procedure [24].
In vivo studies
In vivo antitumor efficacy studies were performed in the
animal facility at Shire BioChem Inc. with the prior
approval of the local Institutional Animal Care Commit-
tee and in agreement with the guidelines provided by
Canadian Council for Animal Care. Female Fox Chase
SCID® mice, between five- and six-weeks old, were pur-
chased from Charles Rivers Laboratories (St-Constant,
Canada). Animals were maintained under specific patho-
gen-free conditions and provided with sterile food and
water ad libitum. The mice were allowed to acclimate for at
least five days. Mice were injected subcutaneously (SC)
with 5 × 106  human pancreatic AsPC-1 tumor cells.
Tumor-bearing animals were randomized (nine per
group) and treatment was started when mean tumor vol-
umes reached 145–150 mm3 (Day 14). Troxacitabine was
administered intravenously (IV) at 1 and 5 mg/kg q3d × 4
and gemcitabine was administered intraperitoneally (IP)
at 80 mg/kg q3d × 4. In the combination studies, drugs
were injected sequentially using the same regimens
(troxacitabine first, followed by gemcitabine 1 h later;
gemcitabine first, followed by troxacitabine 1 h later).
Tumor growth was followed every other day by measuring
tumor length (L) and width (W) using a caliper. Each set
of measurements was converted to tumor volume (TV;
mm3) using the standard formula, TV = (L xW2)/2. The
tumor volume at day n was expressed as the relative tumor
volume (RTV) according to the following formula: RTV =
TVn /TV0, where TVn is the tumor volume at day n (day 45
in this study) and TV0 is the tumor volume at day 14 (time
at which treatment begins). Drug efficacy was assessed at
Day 45, the time at which animals from the control group
had to be sacrificed due to tumor burden, as the percent-
age of T/C, determined by calculating RVT as: T/C% = 100
× (mean RTV  of treated group)/(mean RVT  of control
group). According to the NCI standards, a % T/C ≤ 42 is
indicative of antitumor activity [25-27]. Statistical analy-
sis was calculated by a one-way ANOVA with Dunnett as
a post-test [28] and the two-tailed unpaired t test using
GraphPad prism, version 2.01 (GraphPad Software, San
Diego, CA). Differences were considered to be significant
at P < 0.05. Animals were weighed at least twice weekly
during and after treatment until completion of the study.
The mice were examined frequently for overt signs of any
adverse drug-related side effects. Animals were euthanized
if they showed more than 15% body weight loss for three
consecutive days or >20% body weight loss during a sin-
gle day.
Results
In vitro combination studies with troxacitabine and 
gemcitabine
The four human pancreatic cancer cell lines (AsPC-1,
Capan-2, MIA PaCa-2, and Panc-1) were seeded in 12-
well plates, allowed to attach for 24 h and exposed to
graded concentrations of troxacitabine and gemcitabine,
either alone or in combination for 72 h (Fig. 1). Since
these growth inhibitory studies demonstrated that gemcit-
abine was more potent than troxacitabine in three of the
four cell lines (summarized in Table 1), combination
studies were done using a drug ratio of 1:100 (gemcitab-
ine: troxacitabine) over the range of drug concentrations
tested. Combination treatments yielded significantly
greater growth inhibition than either agent alone in all
cell lines tested (Fig. 1). The isobologram and combina-
tion-index methods developed by Chou and Talalay [21]
were used to confirm and quantify the synergism
observed with gemcitabine and troxacitabine. Isobolo-
grams were constructed for Fa values of 0.50, 0.75, and
0.90, representing 50%, 75% and 90% growth inhibition,
respectively (Fig. 2). The CI values at Fa of 0.5 were calcu-
lated using CalcuSyn software and are summarized in
Table 1. These results indicated that gemcitabine and
troxacitabine were synergistic with CI values of 0.41, 0.71,
0.37, and 0.52, respectively, for Panc-1, MIA PaCa-2,
AsPC-1 and Capan-2 cells. Both methods indicated syner-
gism across a broad range of concentrations in all four
pancreatic tumor cell lines.
Comparison of uptake of [3H]troxacitabine and 
[3H]uridine in pancreatic adenocarcinoma cell lines
The uptake of 10 μM [3H]troxacitabine in Capan-2, AsPC-
1, MIA PaCa-2 and Panc-1 cells was measured at 4-h time
intervals in the absence and presence of excess (100-fold)
non-radioactive troxacitabine. The uptake of 10 μM
[3H]uridine in the absence and presence of excess (100-BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
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fold) non-radioactive uridine to block the transport and
subsequent metabolism steps of the uptake process was
included as a control for comparison; uridine was used
rather than deoxycytidine, which is structurally more
closely related to troxacitabine, because of its higher activ-
ity as a permeant for nucleoside transporters [22]. Relative
accumulation values (pmol/106  cells) of troxacitabine
and uridine in AsPC-1, MIA PaCa-2, Capan-2 and Panc-1
cells are summarized in Table 2. All four cell lines exhib-
ited a large difference in capacity for uptake of 10 μM
[3H]troxacitabine and [3H]uridine, with 100 to 400-fold
greater uptake observed for uridine than for troxacitabine.
The presence of a high concentration (100-fold) of non-
radioactive uridine inhibited uptake of 10 μM [3H]uridine
in all four cell lines by >90%, indicating that uptake,
which included the transport step of the uptake process,
was mediated. In contrast, the presence of high concentra-
tions (100-fold) of non-radioactive troxacitabine had no
effect on the uptake of 10 μM [3H]troxacitabine by any of
the cell lines, suggesting that uptake (and subsequent
Effect of troxacitabine and gemcitabine on growth of human pancreatic tumor cell lines Figure 1
Effect of troxacitabine and gemcitabine on growth of human pancreatic tumor cell lines. Panc-1, MIA PaCa-2, 
AsPc-1 and Capan-2 cells were exposed to graded concentrations of troxacitabine or gemcitabine either alone or in combina-
tion at a ratio of 1:100 of gemcitabine vs. troxacitabine, for 72 h, after which cells were harvested by trypsinization and their 
numbers determined using electronic particle counting. Each data point represents the mean ± SD of three determinations. 
Gemcitabine (open squares), troxacitabine (open inverted triangle), gemcitabine + troxacitabine (open circle). The GI50 values 
for exposures to troxacitabine and gemcitabine alone are given in Table 2.
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metabolism) of troxacitabine was slow, with the permea-
tion step occurring by passive diffusion and/or a low-
affinity transport process, consistent with our previous
findings [11].
Analyses of phosphorylated metabolites of troxacitabine
To understand the biological effects of troxacitabine and
gemcitabine either alone or in combination, [3H]troxacit-
abine metabolites were analyzed under different incuba-
tion conditions as described in Materials and Methods.
The AsPC-1 cell line was chosen for these studies since it
had (i) the highest uptake and accumulation of
[3H]troxacitabine among the four cell lines, and (ii) a
good synergy response. When cells were exposed to equal
concentrations (10 μM) of [3H]troxacitabine and gemcit-
abine, all three troxacitabine phosphorylated species were
reduced by 50% (Table 3). When cells were exposed to 10
μM [3H]troxacitabine in the presence of 0.1 μM gemcitab-
ine, while there was reduction in troxacitabine mono-
phosphate, there was no effect on the di- and tri-
phosphorylated species. No reduction in phosphorylated
metabolites of troxacitabine were observed in AsPC-1 cells
exposed to 300 nM [3H]troxacitabine and 0.5 nM gemcit-
abine for 24 h. We did not observe, in these three different
conditions, changes in troxacitabine incorporation into
DNA in the presence of gemcitabine. When similar exper-
iments were conducted using [3H]gemcitabine to monitor
its metabolites in the presence or absence of troxacitabine,
no changes were observed in pools of phosphorylated
gemcitabine metabolites (data not shown). These results
demonstrated that the synergies observed during in vitro
combination treatments were not caused by changes in
Isobolograms of in vitro drug combinations Figure 2
Isobolograms of in vitro drug combinations. Isobologram analysis of the combination of gemcitabine and troxacitabine in 
Panc-1, MIA PaCa-2, AsPc-1 and Capan-2 cells. The individual doses of gemcitabine and troxacitabine to achieve 90% (straight 
line) growth inhibition (Fa = 0.90), 75% (hyphenated line) growth inhibition (Fa = 0.75), and 50% (dotted line) growth inhibition 
(Fa = 0.50) were plotted on the x- and y-axes. Combination index (CI) values calculated using Calcusyn software is repre-
sented by points above (indicate antagonism between drugs) or below the lines (indicate synergy). (X symbol) ED50, (plus sign) 
ED75 and (open dotted circle ) ED90.
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the relative proportions of phosphorylated metabolites of
troxacitabine and gemcitabine or by an increase in troxac-
itabine incorporation into DNA.
In vivo antitumor efficacy studies
The effects of the combination of troxacitabine and gem-
citabine on human pancreatic AsPC-1 tumor xenografts
were studied to determine if the synergy observed in vitro
between troxacitabine and gemcitabine also occurred in
vivo. Treatment with either troxacitabine (1 and 5 mg/kg
q3d × 4) or gemcitabine (80 mg/kg q3d × 4) was initiated
when tumors were established (mean tumor volumes of
145 to 150 mm3). Treatment was on Days 14, 17, 20, and
23. Sub-optimal doses of troxacitabine were given to
enhance the likelihood of seeing synergism. Interestingly,
the 5 mg/kg troxacitabine dose, which was well below the
maximum tolerated dose [5,29,30], resulted in tumor
regressions occurring from Day 37 till Day 52 with mean
tumor volumes of 133 mm3 to 97 mm3 (P < 0.001). The
% T/C for that group calculated at Day 45 (the time at
which control mice were sacrificed because of tumor bur-
den; Fig 3A) was 12%. No cures were observed and
tumors regrew, reaching a mean of ~300 mm3 at Day 65
(when the experiment was terminated). While the dose of
1 mg/kg was less active than 5 mg/kg, it also exhibited sig-
nificant antitumor activity (T/C of 41% at Day 45, P =
0.0126), although no tumor regressions were observed.
While gemcitabine was administered at a dose and sched-
ule reported to give optimal antitumor efficacy in other
pancreatic tumor models [10], it did not result in signifi-
cant antitumor efficacy in the AsPC-1 pancreatic tumor
model (T/C = 79% at Day 45, P = 0.31).
For the combination studies, we used the lower dose of
troxacitabine (1 mg/kg) since we wanted to improve the
antitumor activity of gemcitabine. Regardless of the
sequence of administration, troxacitabine and gemcitab-
ine had only slight synergistic effects (Fig. 3B and Table 4).
Indeed, the observed T/C at Day 45 was 27% when troxac-
itabine was administered either one hour prior or one
hour after gemcitabine administration. The observed T/C
of 27% at Day 45 was slightly lower than the expected T/
C of 32% (calculated by multiplying the %T/C of each
treatment alone, that is 79% and 41% for gemcitabine
and troxacitabine, respectively). The P  value for the
troxacitabine + gemcitabine combination group was
0.0021 when compared with the saline-treated animals,
and 0.0074 when compared with the gemcitabine-treated
animals. These results indicated that both drugs were
slightly more than additive when combined. While
troxacitabine administered as a single agent at 1 and 5
mg/kg did not result in body weight loss, gemcitabine
treatment (80 mg/kg q3d × 4) resulted in ~8 % body
weight loss from Days 18–27 (Fig 3C). Combination
treatments resulted in up to 15 % body weight loss from
Days 24–27 (Fig 3D). In all groups, body weight increases
were observed after treatment stopped, indicating that the
doses and schedule used were well tolerated.
Discussion
Monotherapy of pancreatic cancer with gemcitabine
results in only a marginal survival benefit [3]. Moreover,
we have previously shown that troxacitabine had activity
in human pancreatic cancers both pre-clinically [10] and
clinically [31]. Although both compounds are deoxycyti-
Table 2: Uptake of 10 μM [3H]troxacitabine and 10 μM [3H]uridine in four pancreatic adenocarcinoma cell lines.
Cell lines [3H]Troxacitabine [3H]Troxacitabine + 1 
mM cold troxacitabine
[3H]Uridine [3H]Uridine + 1 mM 
cold Uridine 
Capan-2 10.2 ± 0.2 10.4 ± 0.1 1028 ± 74 65 ± 6
AsPc-1 19.3 ± 1.5 18.5 ± 1.4 6337 ± 183 326 ± 33
MIA PaCa-2 8.3 ± 0.3 8.2 ± 0.9 3070 ± 244 157 ± 1
Panc-1 12.7 ± 0.8 10.0 ± 0.7 2714 ± 302 158 ± 2
Comparative uptake (4 h) of 10 μM [3H]troxacitabine and 10 μM [3H]uridine in four pancreatic adenocarcinoma cell lines in the absence or 
presence of excess non-radioactive (cold) nucleoside. Each value (pmol/106 cells) represents the mean (± SD) of three determinations.
Table 1: Growth inhibition evaluation of troxacitabine and 
gemcitabine in four pancreatic cell lines.
Cell Line GI50 (nM) ± SEM CIa
Gemcitabine Troxacitabine
Panc-1 4 ± 0.7 40 ± 10 0.41
MIA PaCa-2 13 ± 3 330 ± 20 0.71
AsPC-1 10 ± 2 4 ± 1 0.37
Capan-2 70 ± 20 150 ± 30 0.52
a Fa denotes fraction affected (e.g., Fa of 0.5 is equivalent to a 50% 
reduction in cell growth). CI >1 denotes antagonism, CI = 1 denotes 
additivity, and CI < 1 denotes synergism.
Cells were exposed to graded concentrations of troxacitabine or 
gemcitabine either alone or in combination at a ratio of 1:100 
gemcitabine vs. troxacitabine for 72 h as shown in Fig. 1. Values for 
GI50 (± SEM) (the drug concentration that inhibited cell growth by 
50% as determined from concentration-effect relationships using 
GraphPad Prism version 3.0 software) from three experiments, each 
conducted with three replicates, were calculated from non-linear 
regression analysis of data plotted as percentages of control values 
against the logarithm of drug concentrations. CI (combination index) 
values at a Fa value of 0.5 were generated from the data of Fig. 2 with 
the CalcuSyn, version 2.0 software.BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
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dine nucleoside analogs, troxacitabine is mechanistically
different from gemcitabine (reviewed in references
[29,30]). Its pharmacokinetics are different from those of
most D-nucleoside analogs – e.g., it has an unusually long
terminal half-life (82 h) [32]. Combining two nucleoside
analogs, although a new paradigm in oncology, is a stand-
ard strategy in virology. Because troxacitabine is unique
among anticancer nucleoside drugs in terms of its struc-
ture, pharmacokinetics, intracellular transport, metabo-
lism, and mechanism of action, the current study asked if
troxacitabine and gemcitabine acted synergistically in
pancreatic cancer cell lines and a human pancreatic
xenograft mouse tumor model.
Troxacitabine and gemcitabine demonstrated synergistic
activity in vitro in the four human pancreatic cell lines
tested. Because troxacitabine and gemcitabine both
undergo a series of phosphorylation reactions through a
first rate-limiting step catalyzed by deoxycytidine kinase
(dCK) to form the active triphosphate nucleotide, we
examined if their combined administration resulted in
changes in their respective phosphorylated metabolites.
Since troxacitabine triphosphate is a poor feedback inhib-
itor of dCK [18], it is not likely to limit accumulation of
gemcitabine triphosphate inside cells, and, as expected,
no changes were observed in phosphorylated [3H]gemcit-
abine metabolites in troxacitabine-treated cells (data not
shown). The converse was also true, in that the presence
of gemcitabine did not affect the levels of phosphorylated
[3H]troxacitabine metabolites. These results indicated that
changes in phosphorylated metabolites of either troxacit-
abine or gemcitabine were not responsible for the synergy
observed by combination treatment. A positive interac-
tion between gemcitabine and other nucleoside analogs
have been observed in several previous studies
[18,19,33,34]. Although the molecular mechanism of
potentiation in these studies has been attributed to an
effect on DNA damage, we did not observe differences in
troxacitabine incorporation into DNA or formation of
phosphorylated metabolites in the presence of gemcitab-
ine. The biological basis of this synergy remains unclear;
DNA repair and apoptosis were unchanged by the combi-
nation [35] and thus, we cannot explain the observed syn-
ergy.
Experiments were conducted to determine if the synergy
observed in cultured cell lines when exposed simultane-
ously to gemcitabine and troxacitabine also occurred in
an in vivo human xenograft model of AsPC-1 cells in SCID
mice. The data indicated that, regardless of the sequence
of administration, both troxacitabine and gemcitabine
had greater than additive effects. Thus, the synergy
observed in vitro was extended to in vivo antitumor efficacy
studies at well-tolerated doses and schedules. The results
presented here led to clinical trials of combination ther-
apy with troxacitabine and gemcitabine in pancreatic can-
cer patients. A dose-escalation phase I study of
troxacitabine and gemcitabine was well-tolerated with
doses currently approaching the single-agent mean toler-
ated doses (i.e., 8 mg/m2 troxacitabine on Day 1 with
1,000 mg/m2 gemcitabine on Day 1 and 8 of a 3-week
cycle) [36].
Conclusion
In conclusion, these observations, combined with phase II
studies in which troxacitabine was evaluated as first-line
therapy in 54 patients and gave comparable overall results
to those reported for gemcitabine in randomized trials
Table 3: HPLC analysis of troxacitabine metabolites after exposure to gemcitabine.
Treatment Troxacitabine 
incorporation 
into DNA
(CPM/106 cells)
Metabolites
(pmol/mg protein)
MP DP TP
[3H]Troxacitabine 10 μM
[3H]Troxacitabine 10 μM + 
Gemcitabine 10 μM
1248 ± 153
1226 ± 91
5.0 ± 1.6
2.8 ± 0.9
26.0 ± 7.0
13.0 ± 4.0
6.4 ± 1.5
3.2 ± 1.1
[3H]Troxacitabine 10 μM
[3H]Troxacitabine 10 μM + 
Gemcitabine 0.1 μM
1248 ± 153
1097 ± 298
5.6 ± 1.5
1.7 ± 2.0
22.0 ± 5.0
23.0 ± 2.0
4.5 ± 1.7
5.2 ± 1.0
[3H]Troxacitabine 300 nM
[3H]Troxacitabine 300 nM 
+ Gemcitabine 0.5 nM
4039 ± 118
3838 ± 509
3.0 ± 0.1
2.0 ± 0.2
6.0 ± 0.2
5.9 ± 0.2
2.6 ± 0.3
2.5 ± 0.2
AsPc-1 cells were exposed to [3H]troxacitabine in absence or presence of gemcitabine as described in Materials and Methods. Cells were harvested 
by trypsinization, washed in cold PBS and extracted with 10% TCA for 10 min on ice. The acid-insoluble pellets, containing DNA into which 
[3H]troxacitabine was incorporated, were solubilized in 0.5 N NaOH and their radioactive content was determined. Values are presented as (CPM/
106 cells ± SD). The supernatants, containing phosphorylated metabolites of [3H]troxacitabine, were analyzed by HPLC. Values (pmol/mg protein ± 
SEM) for troxacitabine monophosphate (MP), diphosphate (DP) and triphosphate (TP) are given below.BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
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[31], support further evaluation of troxacitabine in com-
bination with gemcitabine in patients with advanced pan-
creatic cancer.
Abbreviations
Adenosine 5' triphosphate (ATP); Adenosine 5' diphos-
phate; Adenosine 5' monophosphate (AMP); Combina-
tion Index (CI); Deoxycytidine kinase (dCK); Every three
days with a total of 4 administrations (q3d × 4); 5-Fluor-
ouracil (5-FU), High Performance Liquid Chromatogra-
phy (HPLC), Intraperitoneally (IP), Intravenously (IV),
Severe Combined Immune Deficient Mice (SCID®); Sub-
cutaneously (SC); Standard deviation (SD); Standard
error of the mean (SEM); Treated vs. Control (T/C).
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Antitumor activity of troxacitabine and gemcitabine alone (A) or in combination (B) against human pancreatic cancer (AsPc-1)  xenografts Figure 3
Antitumor activity of troxacitabine and gemcitabine alone (A) or in combination (B) against human pancre-
atic cancer (AsPc-1) xenografts.  Female SCID mice were inoculated SC with 5 x 106 AsPc-1 cells (Day 0).  Treatment, 
which was initiated when tumors were established (Day 14), was given on Days 14, 17, 20, and 23.  Troxacitabine was given IV 
at 1 mg/kg (open square) and 5 mg/kg (open losange).  Gemcitabine (open triangle) was administered IP at 80 mg/kg.  The 1 mg/
kg dose of troxacitabine was used for combination studies and drugs were given sequentially, 1h apart: gemcitabine followed by 
troxacitabine (closed triangle); troxacitabine followed by gemcitabine (closed square).  Saline control group (closed circle) was 
given IP at 5 mL/kg (Days 14, 17, 20, and 23). 
10 20 30 40 50 60 70
75
85
95
105
115
Days After Tumor Cell Inoculation
%
 
B
o
d
y
 
W
e
i
g
h
t
10 20 30 40 50 60 70
75
85
95
105
115
Days After Tumor Cell Inoculation
%
 
B
o
d
y
 
W
e
i
g
h
t
AB
CD
10 20 30 40 50 60 70
0
100
200
300
400
500
600
700
Days After Tumor Cell Inoculation
R
e
l
a
t
i
v
e
 
G
r
o
w
t
h
 
(
%
)
10 20 30 40 50 60 70
0
100
200
300
400
500
600
700
Days After Tumor Cell Inoculation
R
e
l
a
t
i
v
e
 
G
r
o
w
t
h
 
(
%
)BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
Page 10 of 11
(page number not for citation purposes)
Authors' contributions
HG was the PI at Shire BioChem and was responsible for
study design, interpretation of the data and revision of the
manuscript.
VLD was responsible for HPLC data acquisition and anal-
ysis of the work presented and the preparation of the man-
uscript.
DYB and LL coordinated and supervised the in vivo stud-
ies.
CEC and JRM coordinated and supervised the growth
inhibition and transport studies.
MG is responsible for troxacitabine activities.
CKW and MLC participated in the study design and anal-
ysis of the growth inhibtion and transport data.
All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Chantal Boudreau, Lilianne Geerts and 
Dominique Custeau for their help with the animal studies; Milada Selner for 
technical assistance with growth inhibition and uptake studies. We also 
thank Jacques Jolivet and Halina Brafman-Labrie for helpful discussions. 
CEC is Canada Research Chair in Oncology. CW held a clinical fellowship 
from the Alberta Heritage Foundation for Medical Research during the 
course of this work. Shire BioChem Inc. supported the work presented 
here.
References
1. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma.  N
Engl J Med 1992, 326(7):455-465.
2. Parikh AA, Lowy AM: Pancreatic cancer: can we screen? How
should we stage?  Curr Gastroenterol Rep 1999, 1(2):166-174.
3. Arbuck SG: Chemotherapy for pancreatic cancer.  Baillieres Clin
Gastroenterol 1990, 4(4):953-968.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML,
Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P,
Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in
survival and clinical benefit with gemcitabine as first-line
therapy for patients with advanced pancreas cancer: a rand-
omized trial.  J Clin Oncol 1997, 15(6):2403-2413.
5. Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, Bowlin T:
Comparative study of a novel nucleoside analogue (Troxatyl,
troxacitabine, BCH-4556) and AraC against leukemic
human tumor xenografts expressing high or low cytidine
deaminase activity.  Cancer Chemother Pharmacol 2001,
47(3):236-240.
6. Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F,
deMuys JM, Bouffard DY, Attardo G: Antitumor activity of
troxacitabine (Troxatyl) against anthracycline-resistant
human xenografts.  Cancer Chemother Pharmacol 2002,
50(6):490-496.
7. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC: Anticancer
activity of beta-L-dioxolane-cytidine, a novel nucleoside ana-
logue with the unnatural L configuration.  Cancer Res 1995,
55(14):3008-3011.
8. Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM,
Bednarski K, Cimpoia A, Attardo G: Potent antitumor activity of
a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-
cytidine), in human renal cell carcinoma xenograft tumor
models.  Cancer Res 1997, 57(21):4803-4810.
9. Rabbani SA, Harakidas P, Bowlin T, Attardo G: Effect of nucleoside
analogue BCH-4556 on prostate cancer growth and metas-
tases in vitro and in vivo.  Cancer Res 1998, 58(15):3461-3465.
10. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD: The new diox-
olane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitab-
ine), has activity against pancreatic human tumor
xenografts.  Clin Cancer Res 2000, 6(4):1574-1578.
11. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A,
Lee N, Mackey JR, Young JD, Jolivet J, Lafreniere RG, Cass CE: Mech-
anisms of uptake and resistance to troxacitabine, a novel
deoxycytidine nucleoside analogue, in human leukemic and
solid tumor cell lines.  Cancer Res 2001, 61(19):7217-7224.
12. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC: Phos-
phorylation of pyrimidine deoxynucleoside analog diphos-
phates: selective phosphorylation of L-nucleoside analog
diphosphates by 3-phosphoglycerate kinase.  J Biol Chem 2002,
277(7):5453-5459.
13. Krishnan P, Gullen EA, Lam W, Dutschman GE, Grill SP, Cheng YC:
Novel role of 3-phosphoglycerate kinase, a glycolytic
enzyme, in the activation of L-nucleoside analogs, a new
Table 4: Troxacitabine and gemcitabine combination studies in the human pancreatic AsPc-1 xenograft tumor model.
Group Dose and Schedule Tumor Volumes 
mm3 Day 45
% T/Ca P values
Compared with 
saline control group
P values
Compared with 
gemcitabine treated group
Control (Saline) 5 mL/kg IV
q3d × 4
804 -
Troxacitabine 1 mg/kg IV
q3d × 4
324 41% P = 0.0126
Troxacitabine 5 mg/kg IV
q3d × 4
90 12% P < 0.001
Gemcitabine 80 mg/kg IP
q3d × 4
631 79% P = 0.31
Troxacitabine + 
Gemcitabine
1 mg/kg IV +
80 mg/kg IP
q3d × 4
215 27% P = 0.0021 P = 0.0074
a Tumor measurements were taken twice weekly. Drug efficacy was assessed at Day 45, time at which animals from the control group had to be 
sacrificed due to tumor burden, as the percentage of T/C, determined by calculating RVT as: T/C% = 100 × (mean RTV of treated group)/(mean 
RVT of control group).
Female SCID mice were inoculated SC with 5 × 106 AsPc-1 cells (Day 0). Treatment with troxacitabine and/or gemcitabine was started 14 days after 
tumor cell inoculation, once the mice had developed palpable tumors.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:121 http://www.biomedcentral.com/1471-2407/7/121
Page 11 of 11
(page number not for citation purposes)
class of anticancer and antiviral agents.  J Biol Chem 2003,
278(38):36726-36732.
14. Krishnan P, Liou JY, Cheng YC: Phosphorylation of pyrimidine L-
deoxynucleoside analog diphosphates. Kinetics of phosphor-
ylation and dephosphorylation of nucleoside analog diphos-
phates and triphosphates by 3-phosphoglycerate kinase.  J Biol
Chem 2002, 277(35):31593-31600.
15. Grove KL, Cheng YC: Uptake and metabolism of the new anti-
cancer compound beta-L-(-)-dioxolane-cytidine in human
prostate carcinoma DU-145 cells.  Cancer Res 1996,
56(18):4187-4191.
16. Chou KM, Kukhanova M, Cheng YC: A novel action of human
apurinic/apyrimidinic endonuclease: excision of L-configura-
tion deoxyribonucleoside analogs from the 3' termini of
DNA.  J Biol Chem 2000, 275(40):31009-31015.
17. Kukhanova M, Liu SH, Mozzherin D, Lin TS, Chu CK, Cheng YC: L-
and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate
analogs as substrates for human DNA polymerases. Implica-
tions for the mechanism of toxicity.  J Biol Chem 1995,
270(39):23055-23059.
18. Bouffard DY, Jolivet J, Leblond L, Hamelin B, Ouellet F, Barbeau S,
Richard A, Gourdeau H: Complementary antineoplastic activ-
ity of the cytosine nucleoside analogues troxacitabine (Trox-
atyl) and cytarabine in human leukemia cells.  Cancer
Chemother Pharmacol 2003, 52(6):497-506.
19. Santini V, Bernabei A, Gozzini A, Scappini B, Zoccolante A, D'Ippolito
G, Figuccia M, Ferrini PR: Apoptotic and antiproliferative effects
of gemcitabine and gemcitabine plus Ara-C on blast cells
from patients with blast crisis chronic myeloproliferative dis-
orders.  Haematologica 1997, 82(1):11-15.
20. Mansour TS, Jin H, Wang W, Hooker EU, Ashman C, Cammack N,
Salomon H, Belmonte AR, Wainberg MA: Anti-human immuno-
deficiency virus and anti-hepatitis-B virus activities and tox-
icities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine
and their 5-fluoro analogues in vitro.  J Med Chem 1995,
38(1):1-4.
21. Chou TC, Talalay P: Quantitative analysis of dose-effect rela-
tionships: the combined effects of multiple drugs or enzyme
inhibitors.  Adv Enzyme Regul 1984, 22:27-55.
22. Cass CE, Young JD, Baldwin SA, Cabrita MA, Graham KA, Griffiths M,
Jennings LL, Mackey JR, Ng AM, Ritzel MW, Vickers MF, Yao SY:
Nucleoside transporters of mammalian cells.  Pharm Biotechnol
1999, 12:313-352.
23. Yamauchi T, Ueda T, Nakamura T: A new sensitive method for
determination of intracellular 1-beta-D-arabinofuranosylcy-
tosine 5'-triphosphate content in human materials in vivo.
Cancer Res 1996, 56(8):1800-1804.
24. Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Ver-
morken JB, Peters GJ: Schedule dependence of sensitivity to
2',2'-difluorodeoxycytidine (Gemcitabine) in relation to
accumulation and retention of its triphosphate in solid
tumour cell lines and solid tumours.  Biochem Pharmacol 1994,
48(7):1327-1339.
25. Alley M.C., Hollingshead M.G., Dykes DJ, Waud WR: Human
Tumor Xenograft Models in NCI Drug Development 125-
152.  In In Cancer Drug Discovery and Development: Anticancer Drug
Development Guide: Preclinical Screening, Clinical Trials, and Approvals
Edited by: Andrews BATPA. Totowa, NJ , Humana Press Inc; 2004. 
26. Corbett T, Polin L, LoRusso P, Valeriote F, Panchapor C, Pugh S,
White K, Knigh J, Demchik L, Jones J, Jones L, Lisow L: In Vivo Meth-
ods for Screening and Preclinical Testing: Use of Rodent
Solid Tumors for Drug Discovery 99-123.  In In Cancer Drug Dis-
covery and Development: Anticancer Drug Development Guide: Preclinical
Screening, Clinical Trials, and Approvals 2nd Ed edition. Edited by:
Andrews BATPA. Totowa, NJ , Humana Press Inc. ; 2004. 
27. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM,
Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M,
Sausville EA: Relationships between drug activity in NCI pre-
clinical in vitro and in vivo models and early clinical trials.  Br
J Cancer 2001, 84(10):1424-1431.
28. Dunnett CW, Tamhane AC: Step-down multiple tests for com-
paring treatments with a control in unbalanced one-way lay-
outs.  Stat Med 1991, 10(6):939-947.
29. Gourdeau H, Jolivet J: [Troxacitabine].  Bull Cancer 2004,
91(3):213-218.
30. Gourdeau H, Jolivet J: Troxacitabine: A Deoxycytidine Nucleo-
side Analog with Potent Antitumor Activity  199-214.  In
Deoxynucleoside Analogs in Cancer Therapy Edited by: Peters GJ.
Totowa, NJ , Humana Press Inc; 2006. 
31. Lapointe R, Letourneau R, Steward W, Hawkins RE, Batist G, Vincent
M, Whittom R, Eatock M, Jolivet J, Moore M: Phase II study of
troxacitabine in chemotherapy-naive patients with advanced
cancer of the pancreas: gastrointestinal tumors.  Ann Oncol
2005, 16(2):289-293.
32. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran
M, Bivins C, Jolivet J, Kantarjian HM: Troxacitabine, a novel diox-
olane nucleoside analog, has activity in patients with
advanced leukemia.  J Clin Oncol 2001, 19(3):762-771.
33. Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan
MK, Chou TC, Fong Y: 5-fluorouracil and gemcitabine potenti-
ate the efficacy of oncolytic herpes viral gene therapy in the
treatment of pancreatic cancer.  J Gastrointest Surg 2005,
9(8):1068-77; discussion 1077-9.
34. Lech-Maranda E, Korycka A, Robak T: The interaction of gemcit-
abine and cytarabine on murine leukemias L1210 or P388
and on human normal and leukemic cell growth in vitro.
Haematologica 2000, 85(6):588-594.
35. Wong C, Clarke ML, Seiner M, Damaraju V, Mackey J, Cass C, Bouf-
fard D, Leblond L, Gourdeau H: Synergistic activity of troxacit-
abine (Troxatyl™) and gemcitabine in pancreatic
adenocarcinoma cell lines.  In Wong C, Clarke ML, Seiner M, Dama-
raju V, Mackey J, Cass C, Bouffard D, Leblond L, Gourdeau H AACR, 94th
Annual Meeting: 2003; Washington DC; 2003. 
36. Von Hoff DD, Jolivet J, Steward WA: A dose-escalating phase I
study of troxacitabine and gemcitabine in advanced solid
malignancies.  Proc Am Soc Clin Oncol 2003 2003:141.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/121/pre
pub